MedPath

Radiation Treatment Of Bladder Cancer With Tomotherapy/ Intensity Modulated Radio Therapy (IMRT)

Not Applicable
Completed
Conditions
Health Condition 1: null- Muscle Invasive Bladder Cancer
Registration Number
CTRI/2009/091/000559
Lead Sponsor
Tata Memorial Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

?Age > 18 years old: Male and Female

?Histologically proven invasive bladder transitional cell carcinoma

?AJCC clinical stages T2-T4a, Nx or N0, M0

?Thorough evaluation by a urologist and have undergone as thorough a TURBT as is judged safely possible

?KPS>= 70

?Able to tolerate systemic chemotherapy combined with pelvic radiation therapy by the joint agreement of the participating Urologist, Radiation Oncologist and Medical Oncologist.

?Hemoglobin >= 10 mg/dl, WBC >= 3000/ml, Absolute neutrophil count of >= 1800/ml, Platelet count of >= 100,000/mm3, Serum creatinine < 1.5 mg%, Serum bilirubin of 2.0mg%

?Ability to take daily treatment

?Only patients with a solitary, well defined tumour will be considered for the boost protocol
?Protocol treatment to begin a maximum of 30 days following TURBT

Exclusion Criteria

Prior pelvic radiation therapy.

? Incontinence, need for cathererisation

?Hydronephrosis attributable to the tumour

? Pregnancy

?Previous malignancy that is likely to interfere with protocol treatment

? Inflammatory bowel disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome of the study is to assess the Dosimetric evaluation of Intensity Modulated Radiotherapy treatment for whole and partial Bladder radiotherapy. , novel Adaptive Radiotherapy Technique and set up errors and Internal organ motion with IGRT.Timepoint: NA
Secondary Outcome Measures
NameTimeMethod
The secondary outcome of the study is to assess the acute and late toxicity, local control and bladder preservation rate.Timepoint: NA
© Copyright 2025. All Rights Reserved by MedPath